CARA THERAPEUTICS INC (CARA)
US1407551092 - Common Stock
We assign a fundamental rating of 3 out of 10 to CARA. CARA was compared to 194 industry peers in the Pharmaceuticals industry. While CARA seems to be doing ok healthwise, there are quite some concerns on its profitability. CARA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CARA has reported negative net income.
In the past year CARA has reported a negative cash flow from operations.
In the past 5 years CARA reported 4 times negative net income.
In the past 5 years CARA always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of CARA (-153.18%) is worse than 85.94% of its industry peers.
With a Return On Equity value of -957.48%, CARA is not doing good in the industry: 83.85% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -153.18% | ||
| ROE | -957.48% | ||
| ROIC | N/A |
ROA(3y)-58.96%
ROA(5y)-43.89%
ROE(3y)-100.1%
ROE(5y)-70.78%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
CARA has a Gross Margin of 74.36%. This is amongst the best in the industry. CARA outperforms 82.29% of its industry peers.
The Profit Margin and Operating Margin are not available for CARA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.36% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
CARA does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CARA has more shares outstanding
Compared to 5 years ago, CARA has more shares outstanding
CARA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CARA has an Altman-Z score of -17.77. This is a bad value and indicates that CARA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -17.77, CARA is doing worse than 85.42% of the companies in the same industry.
There is no outstanding debt for CARA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.77 |
ROIC/WACCN/A
WACC9.03%
2.3 Liquidity
CARA has a Current Ratio of 4.59. This indicates that CARA is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CARA (4.59) is better than 64.58% of its industry peers.
A Quick Ratio of 4.48 indicates that CARA has no problem at all paying its short term obligations.
CARA's Quick ratio of 4.48 is fine compared to the rest of the industry. CARA outperforms 64.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.48 |
3. Growth
3.1 Past
CARA shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.97%.
CARA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -59.45%.
The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)0.97%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.21%
Revenue 1Y (TTM)-59.45%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-85.71%
3.2 Future
Based on estimates for the next years, CARA will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.28% on average per year.
The Revenue is expected to grow by 18.57% on average over the next years. This is quite good.
EPS Next Y39.95%
EPS Next 2Y28.05%
EPS Next 3Y19.43%
EPS Next 5Y11.28%
Revenue Next Year-75.83%
Revenue Next 2Y-51.58%
Revenue Next 3Y-35.75%
Revenue Next 5Y18.57%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CARA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CARA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CARA's earnings are expected to grow with 19.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.05%
EPS Next 3Y19.43%
5. Dividend
5.1 Amount
CARA does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CARA THERAPEUTICS INC
NASDAQ:CARA (11/21/2024, 3:13:02 PM)
0.3072
0 (-0.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap16.85M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -153.18% | ||
| ROE | -957.48% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 74.36% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.59 | ||
| Quick Ratio | 4.48 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)0.97%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y39.95%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-59.45%
Revenue growth 3Y-46.26%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y